Dr. Liou is an Investment Advisor at Bank of America Merrill Lynch specializing in biotech sector since 2014.  Her expertise encompasses both biomedical field with a PhD in cancer biology and immunology, and a CFA designation with active license for Securities Representative (Series 7) and Investment Advisor Representative (Series 66).  Dr. Liou is a co-founder and former CEO of ImmuneTarget.  She also serves as an advisor for several biotechnology companies.

​

Her deep knowledge in basic research and broad network in capital market enables her a unique advantage in advising companies and institutions on business and investment strategies, major advancement in biotechnology, future growth trends, core competency, strategic partnership, asset valuation, and investment opportunities. 

​

At Merrill Lynch, Dr. Liou has designed and managed a Biotech Target Therapy Portfolio for clients. She performs due diligence on biopharmaceutical companies, using metrics including financials, products and clinical pipeline, biotech growth trends, market and competition, management team, and strategic partnership.  

​

Prior to joining Merrill Lynch, Dr. Liou worked as equity analyst covering biotechnology and pharmaceutical companies at Biovantage Investments from 2011 to 2014.  She was a faculty member at Weill Cornell Medical College from 1994 to 2011.  She received her Ph.D. from Harvard School of Public Health and post-doctoral training at MIT and Rockefeller University.  Her biomedical career has generated 90+ publications, 18 awards, and 5 patents.